Log In
BCIQ
Print this Print this
 

MAGH22

  Manage Alerts
Collapse Summary General Information
Company Green Cross Corp.
DescriptionFc-optimized mAb
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationBreast cancer
Indication DetailsTreat breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today